- Home
- TAYD vs BMEA Comparison
TAYD vs BMEA Comparison
Compare TAYD & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAYD
- BMEA
- Stock Information
- Founded
- TAYD 1955
- BMEA 2017
- Country
- TAYD United States
- BMEA United States
- Employees
- TAYD N/A
- BMEA N/A
- Industry
- TAYD Industrial Machinery/Components
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- TAYD Industrials
- BMEA Health Care
- Exchange
- TAYD Nasdaq
- BMEA Nasdaq
- Market Cap
- TAYD 130.2M
- BMEA 145.0M
- IPO Year
- TAYD N/A
- BMEA 2021
- Fundamental
- Price
- TAYD $33.78
- BMEA $3.98
- Analyst Decision
- TAYD
- BMEA Buy
- Analyst Count
- TAYD 0
- BMEA 13
- Target Price
- TAYD N/A
- BMEA $27.92
- AVG Volume (30 Days)
- TAYD 36.9K
- BMEA 939.5K
- Earning Date
- TAYD 01-03-2025
- BMEA 10-29-2024
- Dividend Yield
- TAYD N/A
- BMEA N/A
- EPS Growth
- TAYD 27.48
- BMEA N/A
- EPS
- TAYD 2.70
- BMEA N/A
- Revenue
- TAYD $44,486,041.00
- BMEA N/A
- Revenue This Year
- TAYD N/A
- BMEA N/A
- Revenue Next Year
- TAYD N/A
- BMEA N/A
- P/E Ratio
- TAYD $12.50
- BMEA N/A
- Revenue Growth
- TAYD 8.83
- BMEA N/A
- 52 Week Low
- TAYD $27.82
- BMEA $3.61
- 52 Week High
- TAYD $64.50
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- TAYD 29.16
- BMEA 35.19
- Support Level
- TAYD $32.27
- BMEA $3.78
- Resistance Level
- TAYD $35.25
- BMEA $4.29
- Average True Range (ATR)
- TAYD 1.69
- BMEA 0.29
- MACD
- TAYD -0.24
- BMEA 0.14
- Stochastic Oscillator
- TAYD 14.76
- BMEA 49.26
About TAYD Taylor Devices Inc.
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.